ClinicalTrials.gg
CompletedNCT01604824Updated Jun 17, 2020Results posted

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

A Phase 2 interventional study of Alirocumab and Placebo in Hypercholesterolemia, sponsored by Regeneron Pharmaceuticals. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-06-17.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Feb 2012, registered May 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
39th of 43
23 · median 107
Started
2012
with 11 others
Phase 2
9 of 43
none open now
Registered
11th of 43
by date
Lead sponsor
11 of 43
Regeneron Pharmaceuticals

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 39th largest by enrollment, is one of 12 that started in 2012, is one of 9 in phase 2, and was the 11th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

The primary objective of the study is to assess the pharmacodynamic (PD) effect of alirocumab on serum low density lipoprotein cholesterol (LDL-C) during 14 weeks of subcutaneous (SC) administered alirocumab in patients with autosomal dominant hypercholesterolemia (ADH) and gain-of-function mutation (GOFm) in 1 or both alleles of the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or with loss-of-function mutation (LOFm) in 1 or more alleles of the apolipoprotein (ApoB) gene.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Inclusion criteria include, but are not limited to the following:

  1. Between the ages of 18 and 70 years, inclusive
  2. A history of molecularly confirmed PCSK9 GOFm for cohort 1 and a history of molecularly confirmed PCSK9 GOFm or ApoB LOFm
  3. Plasma LDL-Cholesterol levels ≥70 mg/dL at the screening visit on a lipid-lowering therapy (LLT) regimen stable for at least 28 days

Exclusion criteria

Exclusion Criteria:

Exclusion criteria include, but are not limited to the following:

  1. Serum triglycerides >350 mg/dL at the screening visit
  2. Known to be positive for (HIV), virus, or virus
  3. Pregnant or breast-feeding women.
  4. Sexually active man or woman of who is unwilling to practice adequate during the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    GOFm PCSK9 (Cohort 1): Alirocumab From Day 1

    Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (Cohort 1): Alirocumab 150 mg subcutaneous (SC) injection at Week 0 (Day 1), Week 2 (Day 15), Week 4, 6 and 10 (matching placebo at Week 8, 12 and 14) during the double-blind period (Group A). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.

    Drug: Alirocumab · Drug: Placebo

  • Experimental
    GOFm PCSK9 (Cohort 1): Alirocumab From Day 15

    Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene (Cohort 1): Alirocumab 150 mg subcutaneous (SC) injection at Week 2 (Day 15), Week 4, 6, 8 and 12 (\[matching placebo at Week 0 (Day 1), 10 and 14\]) during the double-blind period (Group B). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.

    Drug: Alirocumab · Drug: Placebo

  • Experimental
    GOFm PCSK9 or LOFm ApoB (Cohort 2): Alirocumab from Day 1

    Participants with gain-of-function mutation (GOFm) in the proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or loss-of-function mutation (LOFm) in the apolipoprotein (Apo) B gene (Cohort 2): Alirocumab 150 mg subcutaneous (SC) injection at Week 0 (Day 1), Week 2 (Day 15), Week 4, 6 and 10 (matching placebo at Week 8, 12 and 14) during the double-blind period (Group C). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.

    Drug: Alirocumab · Drug: Placebo

  • Experimental
    GOFm PCSK9 or LOFm ApoB (Cohort 2): Alirocumab from Day 15

    Participants with gain-of-function mutation (GOFm) in proprotein convertase subtilisin/kexin type 9 (PCSK9) gene or loss-of-function mutation (LOFm) in apolipoprotein (Apo) B gene (Cohort 2): Alirocumab 150 mg subcutaneous (SC) injection at Week 2 (Day 15), Week 4, 6, 8 and 12 (\[matching placebo at Week 0 (Day 1), 10 and 14\]) during the double-blind period (Group D). Afterwards, participants have the possibility to continue in an open-label extension period with 150 mg alirocumab SC twice per week (Q2W) for an additional 3 years.

    Drug: Alirocumab · Drug: Placebo

Interventions

  • SC injection in the abdomen

    Also known as: Praluent®, REGN727, SAR236553

  • DrugPlacebo

    SC injection in the abdomen

06

What researchers measure

Primary outcomes

  1. Percent Change in Measured Serum Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 15

    By day 15, participants in groups A and C had received 1 subcutaneous (SC) dose of 150 mg alirocumab and participants in group B and D had received 1 SC dose of placebo. \[Baseline adjusted least squares (LS) means and standard errors were obtained using analysis of covariance (ANCOVA) model specifying the treatment arm as the fixed effect and the baseline measured LDL-C value as a covariate.\]

    Time frame: Baseline to Day 15

Secondary outcomes

  1. Percent Change in Apolipoprotein (Apo) B100 From Baseline to Day 15

    Baseline adjusted LS means and standard errors were obtained using the same ANCOVA model as for primary endpoint specifying the treatment arm as the fixed effect and the parameter value as a covariate.

    Time frame: Baseline to Day 15

  2. Percent Change in Non High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Day 15

    Time frame: Baseline to Day 15

  3. Percent Change in Total Cholesterol (Total-C) From Baseline to Day 15

    Time frame: Baseline to Day 15

  4. Percent Change in Apolipoprotein (Apo) B100/ ApoA-1 Ratio From Baseline to Day 15

    Time frame: Baseline to Day 15

07

Results

Posted Jun 17, 2020

Participant flow

This study was conducted at 4 sites, 3 in France \& 1 in the United States. Twenty-eight participants were screened between Feb 2012 \& Apr 2013. A total of 23 participants were enrolled: 13 in cohort 1 \& 10 in cohort 2. Recruitment for cohort 2 occurred after the un-blinding of cohort 1 \& analyses of the double-blind study data for cohort 1.

Double-blind (DB) Period
Participant flow — Double-blind (DB) Period
MilestonePCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D)PCSK9 GOFm (Cohort 1: Group A and Group B)PCSK9 GOFm/ApoB LOFm (Cohort 2: Group C and Group D)
Started675500
Completed db period (day 99)675500
Completed db follow-up (day 155)675500
Completed675500
Not completed000000
Open-label Extension (OLE) Period
Participant flow — Open-label Extension (OLE) Period
MilestonePCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D)PCSK9 GOFm (Cohort 1: Group A and Group B)PCSK9 GOFm/ApoB LOFm (Cohort 2: Group C and Group D)
Started00001310
Started open-label extension period00001110
Completed study00001010
Completed00001010
Not completed000030
Withdrew: Chose not to enter ole period000020
Withdrew: Refused to come into office000010

Outcome measures

PrimaryPercent Change in Measured Serum Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 15

By day 15, participants in groups A and C had received 1 subcutaneous (SC) dose of 150 mg alirocumab and participants in group B and D had received 1 SC dose of placebo. \[Baseline adjusted least squares (LS) means and standard errors were obtained using analysis of covariance (ANCOVA) model specifying the treatment arm as the fixed effect and the baseline measured LDL-C value as a covariate.\]

Time frame:
Baseline to Day 15
Reported as:
Least squares mean · percent change
Percent Change in Measured Serum Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 15
percent changePCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D)
Percent Change in Measured Serum Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Day 15-62.48 ± 8.217-8.77 ± 7.575-48.21 ± 7.660-4.93 ± 7.660
Statistical analysis
  • PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) vs PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) · ANCOVA · p = = 0.0009 (Threshold for significance ≤ 0.05) · Ls mean difference: -53.72 · 95% CI -79.31 to -28.12
  • PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) vs PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) · ANCOVA · p = = 0.0056 (Threshold for significance ≤ 0.05) · Ls mean difference: -43.28 · 95% CI -69.21 to 17.35
SecondaryPercent Change in Apolipoprotein (Apo) B100 From Baseline to Day 15

Baseline adjusted LS means and standard errors were obtained using the same ANCOVA model as for primary endpoint specifying the treatment arm as the fixed effect and the parameter value as a covariate.

Time frame:
Baseline to Day 15
Reported as:
Least squares mean · percent change
Percent Change in Apolipoprotein (Apo) B100 From Baseline to Day 15
percent changePCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D)
Percent Change in Apolipoprotein (Apo) B100 From Baseline to Day 15-53.33 ± 8.678-3.78 ± 8.008-47.73 ± 7.547-3.09 ± 7.547
Statistical analysis
  • PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) vs PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) · ANCOVA · p = = 0.0021 (Threshold for significance ≤ 0.05) · Ls mean difference: -49.55 · 95% CI -76.39 to -22.7
  • PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) vs PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) · ANCOVA · p = = 0.0045 (Threshold for significance ≤ 0.05) · Ls mean difference: -44.64 · 95% CI -70.36 to 18.92
SecondaryPercent Change in Non High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Day 15
Time frame:
Baseline to Day 15
Reported as:
Least squares mean · percent change
Percent Change in Non High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Day 15
percent changePCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D)
Percent Change in Non High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Day 15-56.87 ± 8.217-7.50 ± 7.575-44.40 ± 7.357-4.04 ± 7.357
Statistical analysis
  • PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) vs PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) · ANCOVA · p = = 0.0016 (Threshold for significance ≤ 0.05) · Ls mean difference: -49.37 · 95% CI -74.96 to -23.77
  • PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) vs PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) · ANCOVA · p = = 0.0063 (Threshold for significance ≤ 0.05) · Ls mean difference: -40.36 · 95% CI -65.12 to 15.60
SecondaryPercent Change in Total Cholesterol (Total-C) From Baseline to Day 15
Time frame:
Baseline to Day 15
Reported as:
Least squares mean · percent change
Percent Change in Total Cholesterol (Total-C) From Baseline to Day 15
percent changePCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D)
Percent Change in Total Cholesterol (Total-C) From Baseline to Day 15-36.94 ± 5.203-6.18 ± 4.802-29.40 ± 4.422-7.18 ± 4.422
Statistical analysis
  • PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) vs PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) · ANCOVA · p = = 0.0017 (Threshold for significance ≤ 0.05) · Ls mean difference: -30.75 · 95% CI -46.85 to -14.66
  • PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) vs PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) · ANCOVA · p = = 0.0096 (Threshold for significance ≤ 0.05) · Ls mean difference: -22.23 · 95% CI -37.11 to -7.34
SecondaryPercent Change in Apolipoprotein (Apo) B100/ ApoA-1 Ratio From Baseline to Day 15
Time frame:
Baseline to Day 15
Reported as:
Least squares mean · percent change
Percent Change in Apolipoprotein (Apo) B100/ ApoA-1 Ratio From Baseline to Day 15
percent changePCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D)
Percent Change in Apolipoprotein (Apo) B100/ ApoA-1 Ratio From Baseline to Day 15-55.26 ± 7.188-5.53 ± 6.647-48.34 ± 8.0900.99 ± 8.090
Statistical analysis
  • PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A) vs PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B) · ANCOVA · p = = 0.0005 (Threshold for significance ≤ 0.05) · Ls mean difference: -49.72 · 95% CI -71.71 to -27.74
  • PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C) vs PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D) · ANCOVA · p = = 0.0037 (Threshold for significance ≤ 0.05) · Ls mean difference: -49.33 · 95% CI -76.63 to -22.03

Adverse events

Collected over From the screening visit after the last alirocumab injection in the open-label period + 70 days through the end of study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)0/6 (0%)1/6 (16.7%)6/6 (100%)
PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)0/7 (0%)0/7 (0%)6/7 (85.7%)
PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)0/5 (0%)0/5 (0%)5/5 (100%)
PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2:Group D)0/5 (0%)0/5 (0%)4/5 (80%)
OLE Period: PCSK9 GOFm (Cohort 1) Group A & Group B0/11 (0%)3/11 (27.3%)10/11 (90.9%)
OLE Period: PCSK9 GOFm/ ApoB LOFm (Cohort 2) Group C & Group D0/10 (0%)0/10 (0%)9/10 (90%)
Most frequent serious events
Most frequent serious events
EventPCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2:Group D)OLE Period: PCSK9 GOFm (Cohort 1) Group A & Group BOLE Period: PCSK9 GOFm/ ApoB LOFm (Cohort 2) Group C & Group D
Chest painGeneral disorders1/60/70/50/51/110/10
Angina unstableCardiac disorders0/60/70/50/51/110/10
Myocardial ischaemiaCardiac disorders0/60/70/50/51/110/10
Salivary gland disorderGastrointestinal disorders0/60/70/50/51/110/10
ObesityMetabolism and nutrition disorders0/60/70/50/51/110/10
Most frequent other events
Showing 10 of 100
Most frequent other events
EventPCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2:Group D)OLE Period: PCSK9 GOFm (Cohort 1) Group A & Group BOLE Period: PCSK9 GOFm/ ApoB LOFm (Cohort 2) Group C & Group D
Viral upper respiratory tract infectionInfections and infestations2/61/72/51/54/112/10
GastroenteritisInfections and infestations2/61/71/50/50/111/10
HeadacheNervous system disorders0/62/70/51/50/110/10
VertigoEar and labyrinth disorders0/60/70/51/50/111/10
Abdominal discomfortGastrointestinal disorders1/60/70/51/50/110/10
Abdominal distensionGastrointestinal disorders0/60/70/51/50/110/10
Chest painGeneral disorders1/60/70/51/51/110/10
Herpes zosterInfections and infestations0/60/70/51/50/110/10
InfluenzaInfections and infestations0/60/71/50/50/110/10
Lower respiratory tract infectionInfections and infestations1/60/71/51/50/111/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D)Total
Mean42.3 ± 14.7246.4 ± 13.2445.6 ± 3.2142.0 ± 10.8444.2 ± 11.15
Age, Customized
Age, Customized(Participants)PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D)Total
In utero00000
Preterm newborn infants (gestational age < 37 wks)00000
Newborns (0-27 days)00000
Infants and toddlers (28 days-23 months)00000
Children (2-11 years)00000
Adolescents (12-17 years)00000
Adults (18-64 years)675523
From 65-84 years00000
85 years and over00000
Sex: Female, Male
Sex: Female, Male(Participants)PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D)Total
Female454215
Male22138
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D)Total
Hispanic or Latino00000
Not Hispanic or Latino675523
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D)Total
White565521
Black or African American00000
Asian00000
American Indian or Alaska Native00000
Native Hawaiian or Other Pacific Islander00000
Other: Indian Ocean Islander01001
Other: Mauritius10001
Measured Low-Density Lipoprotein Cholesterol (LDL-C)
Measured Low-Density Lipoprotein Cholesterol (LDL-C)(milligrams per deciliter (mg/dL))PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D)Total
Mean108.8 ± 33.84144.3 ± 68.39187.4 ± 98.12151.0 ± 82.70145.9 ± 72.82
Total Cholesterol
Total Cholesterol(mg/dL)PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D)Total
Mean181.3 ± 41.89216.3 ± 78.61249.8 ± 86.68226.0 ± 77.80216.6 ± 71.84
Non-high-density lipoprotein cholesterol (Non-HDL-C)
Non-high-density lipoprotein cholesterol (Non-HDL-C)(mg/dL)PCSK9 GOFm: Alirocumab From Day 1 (Cohort 1: Group A)PCSK9 GOFm: Alirocumab From Day 15 (Cohort 1: Group B)PCSK9 GOFm/ApoB LOFm: Alirocumab From Day1 (Cohort 2: Group C)PCSK9GOFm/ApoB LOFm: Alirocumab From Day 15(Cohort 2: Group D)Total
Mean124.3 ± 49.00165.9 ± 75.59189.4 ± 93.43163.4 ± 86.88159.6 ± 74.97

2 further baseline measures are reported on the registry.

08

Study locations

4 sites
  • Salt Lake City, Utah, United States
  • Lille, Cedex, France
  • Nantes, Cedex, France
  • Paris, France
09

References and documents

Publications

  • Hopkins PN, Krempf M, Bruckert E, Donahue S, Yang F, Zhang Y, DiCioccio AT. Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations. J Clin Lipidol. 2019 Nov-Dec;13(6):970-978. doi: 10.1016/j.jacl.2019.10.007. Epub 2019 Oct 21. PubMed 31767518 ↗
  • Hopkins PN, Defesche J, Fouchier SW, Bruckert E, Luc G, Cariou B, Sjouke B, Leren TP, Harada-Shiba M, Mabuchi H, Rabes JP, Carrie A, van Heyningen C, Carreau V, Farnier M, Teoh YP, Bourbon M, Kawashiri MA, Nohara A, Soran H, Marais AD, Tada H, Abifadel M, Boileau C, Chanu B, Katsuda S, Kishimoto I, Lambert G, Makino H, Miyamoto Y, Pichelin M, Yagi K, Yamagishi M, Zair Y, Mellis S, Yancopoulos GD, Stahl N, Mendoza J, Du Y, Hamon S, Krempf M, Swergold GD. Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. Circ Cardiovasc Genet. 2015 Dec;8(6):823-31. doi: 10.1161/CIRCGENETICS.115.001129. Epub 2015 Sep 15. PubMed 26374825 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2012 to primary completion in Jun 2014, 27 months.

Results were first posted in Jun 2020, 6 years after primary completion. A results delay was requested in Jan 2015.

Of 41 industry-sponsored phase 2 interventional studies under Hypercholesterolemia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 14. This study's 27 months is above that.

Counting every sponsor, half of 48 studies reached it within 10 months; a quarter within 7 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2012
First posted
May 24, 2012
StartActual
Feb 22, 2012
Primary completionActual
Jun 2, 2014
CompletionActual
Jul 28, 2017
Results delay requested
Jan 24, 2015
Results first posted
Jun 17, 2020
Last update
Jun 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01604824
Collaborators
Sanofi
Responsible party
Sponsor
First posted
May 24, 2012
Start date
Feb 22, 2012
Primary completion
Jun 2, 2014
Completion
Jul 28, 2017
Results posted
Jun 17, 2020
Last update
Jun 17, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion